Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ramathibodi Hospital
• Treatments: Alfacalcidol; Hydroxycholecalciferols

Criteria

Inclusion Criteria:

• Predialysis chronic kidney disease with GFR < 90 mL/min/1.73m2

• PTH above the upper limit of normal

• serum calcium and phosphate below the upper limit of normal

Exclusion Criteria:

• changes in GFR>15% during the past 3 months

• receive elemental calcium>500 mg/day

• currently taking active vitamin D, oral calcium with elemental calcium>500 mg/day or bisphosphonate